What Is GMP Compliance for CDMO Manufacturing?
Good Manufacturing Practice compliance is the regulatory and operational baseline that every Contract Development and Manufacturing Organisation must maintain to legally produce pharmaceutical products for human or animal use. When selecting a CDMO partner for injectable or semi-solid dosage form manufacturing, the depth and breadth of that compliance determines not only the safety and quality of your product but also the viability of your path to market authorisation.
This article sets out the Good Manufacturing Practice certifications, aseptic manufacturing standards and quality criteria that pharmaceutical and biotechnology development and manufacturing leaders should assess before committing to a Contract Development and Manufacturing Organisation partnership for sterile injectable or semi-solid pharmaceutical manufacturing.
What Is Good Manufacturing Practice Compliance for a CDMO?
Good Manufacturing Practice compliance for a Contract Development and Manufacturing Organisation is a continuously maintained state of facility, personnel, process and documentation readiness, verified through regular inspections by international health authorities. It is not a single certification issued once. A CDMO that holds multi-authority Good Manufacturing Practice certification demonstrates the operational capability to supply product across multiple regulatory jurisdictions from a single manufacturing relationship.
Good Manufacturing Practice is a system of controls governing the conditions and methods used to produce, process, package and hold pharmaceutical products. The primary regulatory frameworks governing these standards include the European Union’s EudraLex Volume 4, the United States Food and Drug Administration’s Current Good Manufacturing Practice regulations and the quality guidelines established by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.
For a Contract Development and Manufacturing Organisation, compliance is verified through periodic inspections by health authorities including the European Medicines Agency, Swissmedic, the United States Food and Drug Administration and the Pharmaceuticals and Medical Devices Agency in Japan, among others. The outcome of each inspection, and the quality of the Corrective and Preventive Action process that follows, is as informative as the certificate itself when assessing a prospective manufacturing partner.
Good Manufacturing Practice Certifications to Assess When Selecting a CDMO
The Good Manufacturing Practice certifications held by a Contract Development and Manufacturing Organisation should align directly with the markets in which you intend to commercialise your product. Certifications from multiple international health authorities provide the broadest commercial reach from a single manufacturing partnership, without requiring separate facility qualifications for each target market.
The most significant certifications to assess are:
- European Union Good Manufacturing Practice (EudraLex Volume 4): Required for distribution within the European Union and referenced as a baseline standard by many other regulatory jurisdictions worldwide.
- United States Food and Drug Administration Current Good Manufacturing Practice: Required for distribution within the United States and broadly accepted internationally as a leading indicator of manufacturing quality.
- Swissmedic Good Manufacturing Practice: Required for Swiss-based manufacturing operations and internationally respected for its regulatory rigour and consistency.
- Japan Pharmaceuticals and Medical Devices Agency Good Manufacturing Practice: Required for pharmaceutical products entering the Japanese market, which is recognised as one of the most demanding quality environments in the global pharmaceutical industry.
- Additional international health authority certifications: Depending on your target markets, these may include Brazil’s Agência Nacional de Vigilância Sanitária, China’s National Medical Products Administration, Australia’s Australian Register of Therapeutic Products, South Korea’s Korea Food and Drug Administration and others.
When evaluating a Contract Development and Manufacturing Organisation, request its current Good Manufacturing Practice certification schedule, the date of its most recent regulatory authority inspection and the outcome of any resulting Corrective and Preventive Action processes. A CDMO that handles audits transparently and with a low number of repeated observations provides a stronger quality signal than one that simply lists its certifications.
Aseptic Manufacturing Standards for Injectable Production
For injectable products including liquid vials, lyophilised vials and prefilled syringes, the regulatory standard is set at a higher threshold than for any other dosage form category. Aseptic manufacturing requires strict environmental controls, validated sterilisation processes and robust container closure integrity assurance. The following are the key technical and regulatory standards to assess in a Contract Development and Manufacturing Organisation’s injectable manufacturing capability.
Restricted Access Barrier Systems
Restricted Access Barrier System technology provides a physical separation between the fill zone and the operator, significantly reducing the risk of microbial contamination during open processing steps. Both European Medicines Agency Good Manufacturing Practice Annex 1 and United States Food and Drug Administration guidance documents expect modern aseptic facilities to implement Restricted Access Barrier System or isolator technology as standard in fill-and-finish operations. A Contract Development and Manufacturing Organisation operating without one of these barrier systems presents a higher contamination risk profile that regulators will assess during any technology transfer review.
Aseptic Process Simulation
Aseptic Process Simulation, also known as media fill testing, is the validated procedure by which a Contract Development and Manufacturing Organisation demonstrates that its filling operations can be performed aseptically without contamination. Full Aseptic Process Simulation compliance, including documented passing results, is a non-negotiable quality criterion for any CDMO considered for injectable production. When assessing this criterion, confirm that Aseptic Process Simulation results are current, documented and available for review during a sponsor quality audit.
Lyophilisation Capability
For biological products and small molecules with limited solution stability, lyophilisation is a frequently required manufacturing step. When assessing a Contract Development and Manufacturing Organisation’s freeze-drying capability, confirm the validated lyophiliser capacity, the documented loading and unloading procedures, cycle development expertise and the availability of process qualification data. A facility offering multiple lyophiliser capacities provides greater flexibility across different batch sizes and molecule classes.
Automated Visual Inspection
Regulatory requirements, particularly within the Japanese market, demand rigorous visual inspection of injectable products. Both automated and manual inspection capabilities should be reviewed, including the inspection throughput in units per minute, defect detection methodology covering optical, cosmetic and pinhole detection modalities, and compliance with the relevant pharmacopoeial standards. A common and underappreciated readiness gap occurs when a Contract Development and Manufacturing Organisation’s inspection capacity cannot keep pace with its filling line throughput, creating batch release bottlenecks at exactly the moment commercial supply pressure is highest.
Cleaning-In-Place and Sterilisation-In-Place Systems
Cleaning-In-Place and Sterilisation-In-Place systems allow manufacturing equipment to be cleaned and sterilised without disassembly, reducing contamination risk and maintaining validated cleaning procedures across product changeovers. Any Contract Development and Manufacturing Organisation operating multi-product aseptic filling lines must demonstrate validated Cleaning-In-Place and Sterilisation-In-Place protocols with documented cycle qualification data. The absence of these systems on aseptic lines is a significant quality and regulatory risk factor when evaluating a prospective partner.
Good Manufacturing Practice Requirements for Semi-Solid Dosage Form Manufacturing
Good Manufacturing Practice compliance for semi-solid manufacturing, covering creams, gels, ointments and healing pastes, differs from sterile injectable standards but remains subject to full regulatory oversight under EudraLex Volume 4. The most relevant quality criteria are process scalability, in-process environmental controls, microbiology monitoring and on-site analytical capability.
The following criteria are material when assessing a Contract Development and Manufacturing Organisation for semi-solid pharmaceutical manufacturing:
- Validated batch sizes and process scalability: A Contract Development and Manufacturing Organisation should demonstrate validated manufacturing processes across its full batch size range, not solely at a single representative scale. For sponsors transferring a process from development to commercial manufacturing, confirmation of validated scale-up data is essential before the transfer commences.
- In-process environmental controls: Temperature and humidity control during heating, cooling, homogenisation and deaeration steps are critical determinants of product consistency and batch-to-batch reproducibility. These controls must be documented within validated process parameters and monitored throughout each production run.
- Microbiology controls for non-sterile products: Even where a product is not classified as sterile, Total Aerobic Microbial Count and Total Yeast and Mould Count testing must be routinely conducted and monitored against validated specifications in accordance with pharmacopoeial requirements.
- On-site analytical capability: High-Performance Liquid Chromatography, Gas Chromatography and dissolution testing capabilities should be available on-site or through formally validated contract analytical partnerships with documented qualification data.
- International Council for Harmonisation-compliant stability testing: The Contract Development and Manufacturing Organisation should be equipped to conduct stability studies under International Council for Harmonisation Zone II, IVa and IVb conditions, with alarm-controlled monitoring of temperature and humidity throughout the storage period.
Technology Transfer and Good Manufacturing Practice Manufacturing Readiness
Good Manufacturing Practice certification alone does not guarantee a smooth technology transfer. A Contract Development and Manufacturing Organisation may hold current certifications and still lack the structured project management infrastructure needed to execute a transfer efficiently. Technology transfer readiness must be assessed as a distinct capability, separate from manufacturing capability, during the partner evaluation process.
When evaluating a Contract Development and Manufacturing Organisation’s technology transfer readiness, the following criteria are material:
- Documented technology transfer protocols: The Contract Development and Manufacturing Organisation should have defined, structured procedures for receiving, validating and scaling a process transferred from a sponsor’s development organisation or from another manufacturing site. Request a redacted example technology transfer plan to confirm the level of documentation discipline in place.
- Qualified Person-led batch certification: Within the European Union, a licensed Qualified Person must certify each batch prior to release. Confirm that your Contract Development and Manufacturing Organisation has in-house Qualified Person capability and that its batch release process is compatible with your programme’s development timeline and regulatory submission requirements.
- Analytical method transfer and validation: The Contract Development and Manufacturing Organisation should have the capability to receive, qualify and routinely perform your product’s analytical test methods, including sterility suitability testing, endotoxin suitability testing and bioburden suitability testing where applicable.
- Chemistry, Manufacturing and Controls documentation support: For sponsors preparing regulatory dossiers, a Contract Development and Manufacturing Organisation that offers Chemistry, Manufacturing and Controls documentation support reduces coordination complexity and the risk of submission-critical errors arising from misaligned process descriptions between sites.
Adragos Pharma’s Good Manufacturing Practice-Certified Manufacturing Network
Adragos Pharma operates a network of seven Good Manufacturing Practice-certified facilities across Europe and Japan. Each site maintains current certification from multiple international health authorities, providing sponsors with flexible global supply options within a single Contract Development and Manufacturing Organisation relationship.
Sterile Injectable Manufacturing at Commercial Scale: Adragos Maisons-Alfort, France
Adragos Maisons-Alfort operates at large commercial scale for prefilled syringes, liquid vials and lyophilised vials. With over 77 years of specialisation in sterile drug manufacturing, the facility holds European Union Good Manufacturing Practice certification and is certified by 12 international health authorities. Two Restricted Access Barrier System-equipped prefilled syringe filling lines achieve a maximum throughput of up to 540 units per minute. Full Aseptic Process Simulation compliance and Cleaning-In-Place and Sterilisation-In-Place systems are integrated across all aseptic processing environments. Two Seidenader automated inspection lines operate at up to 600 units per minute, providing 100% inspection throughput that exceeds filling line capacity and eliminates structural batch release bottlenecks. Annual production capacity reaches up to 150 million prefilled syringe units.
Sterile Ampoule and Suppository Manufacturing: Adragos Livron, France
Adragos Livron specialises in sterile ampoule manufacturing and suppositories, with over 110 years of manufacturing experience. The site operates four production lines, including two aseptic lines equipped with Restricted Access Barrier System technology and two non-aseptic lines, supporting both aseptic filling and terminal sterilisation processes. Batch sizes range from 30 to 1,500 litres with a total ampoule capacity of 120 million units per year. Current certifications include European Union Good Manufacturing Practice, France’s Agence Nationale de Sécurité du Médicament et des Produits de Santé, France’s Agence nationale de sécurité sanitaire de l’alimentation, de l’environnement et du travail and South Korea’s Korea Food and Drug Administration.
Intravenous Bag and Blow-Fill-Seal Manufacturing: Adragos Halden, Norway
For sponsors requiring intravenous bag and Blow-Fill-Seal ampoule manufacturing, Adragos operates a partner site in Halden, Norway. The Halden facility holds European Union Good Manufacturing Practice, United States Food and Drug Administration, Brazilian Agência Nacional de Vigilância Sanitária, Japan Pharmaceuticals and Medical Devices Agency, Chinese National Medical Products Administration and additional international health authority certifications, supplying pharmaceutical products to more than 75 countries worldwide.
Semi-Solid and Non-Sterile Liquid Manufacturing: Adragos Leipzig, Germany
Adragos Leipzig holds European Union Good Manufacturing Practice certification for both human and animal pharmaceutical products, with a production history spanning 100 years. The facility operates two validated semi-solid production lines with batch sizes from 15 to 1,250 litres, and three non-sterile liquid production lines with batch sizes up to 4,000 litres. On-site analytical capability includes High-Performance Liquid Chromatography, Gas Chromatography and microbiology testing covering Total Aerobic Microbial Count and Total Yeast and Mould Count. Stability studies are conducted under International Council for Harmonisation Zones II, IVa and IVb, with alarm-controlled environmental monitoring throughout the storage period. Services extend from galenical development and pilot batches through to full batch certification by a Qualified Person, serialisation and product quality reviews.
Japanese Market Quality Standards: Adragos Kawagoe, Japan
Adragos Kawagoe in Japan provides visual inspection and packaging services for finished pharmaceutical products entering the Japanese market, with over 50 years of operational experience. The site’s processes are aligned with Pharmaceuticals and Medical Devices Agency requirements and Japan’s zero-defect quality expectations, enabling sponsors to access one of the world’s most demanding pharmaceutical markets through a locally established partner without the need for a separate manufacturing facility qualification in Japan.
Good Manufacturing Practice Compliance Evaluation: A Summary Checklist
Before committing to a Contract Development and Manufacturing Organisation for pharmaceutical manufacturing, use the checklist below to confirm that the most material Good Manufacturing Practice criteria are satisfied for your programme. Each criterion should be formally verified rather than accepted on the basis of a facility’s own assertions.
| Assessment Criterion | What to Confirm |
|---|---|
| Regulatory certification scope | Current Good Manufacturing Practice certificates verified for all target launch markets; inspection history reviewed; Corrective and Preventive Action records assessed for repeated observations |
| Aseptic environment technology | Restricted Access Barrier System or isolator technology in use on all fill-finish lines; Cleaning-In-Place and Sterilisation-In-Place systems validated across all aseptic processing equipment |
| Aseptic Process Simulation | Full Aseptic Process Simulation compliance documented and current; passing results available for review during quality audit |
| Visual inspection capability | Inspection throughput meets or exceeds filling line capacity; optical, cosmetic and pinhole detection modalities confirmed; manual inspection available where market-required |
| Lyophilisation infrastructure | Lyophiliser capacity and validated cycle data confirmed for your batch size range; loading and unloading procedures documented |
| Semi-solid process validation | Validated batch records available across full production scale range; in-process microbiology controls documented; scale-specific process data available for review |
| Analytical and stability capability | In-house High-Performance Liquid Chromatography and Gas Chromatography capability confirmed; International Council for Harmonisation-compliant stability storage available on site with alarm-controlled monitoring |
| Technology transfer infrastructure | Documented transfer protocols in place; in-house Qualified Person for batch certification confirmed; analytical method transfer and validation capability verified |
| Audit transparency | Most recent inspection reports reviewed; number and nature of observations assessed; Corrective and Preventive Action closure rates confirmed prior to agreement |
Frequently Asked Questions
What does Good Manufacturing Practice compliance mean for pharmaceutical manufacturing?
Good Manufacturing Practice is a system of regulatory controls governing the conditions and methods used to produce, process, package and hold pharmaceutical products. For pharmaceutical manufacturing, it defines the minimum acceptable standards for personnel, facilities, equipment, documentation and quality systems. Compliance is verified through inspections by national and international health authorities. A product manufactured at a non-compliant facility cannot legally be placed on regulated markets, irrespective of its analytical test results.
What Good Manufacturing Practice certifications should a CDMO hold for sterile injectable manufacturing?
As a baseline, a Contract Development and Manufacturing Organisation should hold a current European Union Good Manufacturing Practice certificate under EudraLex Volume 4. For programmes targeting the United States, current United States Food and Drug Administration inspection readiness is essential. For Swiss-based manufacturing sites, Swissmedic certification is required. Facilities certified by multiple international health authorities provide the broadest commercial reach from a single manufacturing relationship without requiring additional facility audits for each new market.
What is Aseptic Process Simulation and why is it required for injectable manufacturing?
Aseptic Process Simulation, commonly referred to as a media fill, is a validated test procedure in which a microbiological growth medium is processed through an aseptic filling operation in place of a pharmaceutical product. The purpose is to demonstrate that the manufacturing process, equipment, environment and personnel can consistently produce sterile units without contamination. Both European Medicines Agency Annex 1 and United States Food and Drug Administration guidance require Aseptic Process Simulation to be conducted at defined intervals and following any process change that could affect sterility assurance. Documented passing results must be available for review during sponsor quality audits.
What is the difference between Restricted Access Barrier System and isolator technology in aseptic manufacturing?
Both Restricted Access Barrier System and isolator technologies provide a physical barrier between the aseptic fill zone and the operator, reducing the risk of microbial contamination during open processing. The primary distinction is the degree of separation: isolators provide a fully enclosed environment with a higher sterility assurance level, while Restricted Access Barrier Systems combine semi-closed barrier protection with greater operational flexibility at high filling speeds. Both technologies are accepted by regulatory authorities as meeting the contamination control requirements of modern aseptic manufacturing under current Good Manufacturing Practice frameworks. The appropriate technology for a given programme depends on the product characteristics, manufacturing scale and regulatory markets targeted.
How does Good Manufacturing Practice compliance affect a pharmaceutical technology transfer to a CDMO?
Good Manufacturing Practice compliance is the regulatory prerequisite for a technology transfer to generate commercially or clinically usable product. However, compliance status does not, by itself, determine how efficiently the transfer will execute. A facility must also have structured technology transfer protocols, in-house Qualified Person capability, validated analytical method transfer procedures and Chemistry, Manufacturing and Controls documentation expertise. Sponsors should assess both the compliance status and the transfer infrastructure of any prospective Contract Development and Manufacturing Organisation partner before commencing a transfer programme.
What quality standards apply to semi-solid dosage form manufacturing at a CDMO?
Semi-solid dosage form manufacturing is subject to full European Union Good Manufacturing Practice requirements under EudraLex Volume 4, even though the sterility assurance requirements differ from those for injectable products. Key quality standards include validated batch records across all production scales, in-process temperature and humidity controls during homogenisation and deaeration, microbiology testing for Total Aerobic Microbial Count and Total Yeast and Mould Count, on-site High-Performance Liquid Chromatography and Gas Chromatography capability, and stability testing under International Council for Harmonisation Zone II, IVa and IVb conditions.
Discuss Your Manufacturing Programme with Adragos Pharma
Adragos Pharma is a global Contract Development and Manufacturing Organisation operating seven Good Manufacturing Practice-certified facilities across Europe and Japan, certified by multiple international health authorities including the European Medicines Agency, the United States Food and Drug Administration, Swissmedic and the Pharmaceuticals and Medical Devices Agency.
Whether you are evaluating CDMO services for sterile injectable pharmaceutical manufacturing, semi-solid dosage form production or a programme spanning multiple dosage forms and markets, our team is available to conduct a site-specific capability assessment against your product profile and regulatory requirements.
Visit adragos-pharma.com to contact our manufacturing team and initiate a capability review.
